About Simulations Plus
Simulations Plus is a leading provider of modeling and simulation software and consulting services for pharmaceutical and biotechnology companies. For over 30 years, the company has partnered with scientists and teams across the drug development lifecycle, supporting ADMET prediction, physiologically-based pharmacokinetic (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology (QSP/QST). The company's flagship products include GastroPlus for PBPK modeling, MonolixSuite for pharmacometrics, ADMET Predictor for machine learning-based ADMET modeling, DILIsym for quantitative systems toxicology, and Thales for QSP modeling. Simulations Plus serves 19 out of the top 20 pharmaceutical companies globally, with over 280 clients worldwide. The company combines mechanistic models with AI-enabled workflows in an integrated environment, helping clients move from discovery to regulatory submission with confidence. In addition to software, Simulations Plus offers expert consulting services across discovery, development, clinical operations, and commercialization phases. The company collaborates extensively with academic institutions, CROs, regulatory agencies including the FDA, EPA, and NIH, and maintains strong distributor networks in Brazil, China, India, Japan, and South Korea. Simulations Plus has entered into an agreement to be acquired by Altaris, a healthcare-focused investment firm, and will be combined with Chemical Computing Group.
Mission & Story
Mission
We Improve Quality of Life Through Innovative Solutions
Clinical Focus
Medical conditions and clinical areas addressed by Simulations Plus.
Who It Serves
Milestones & Awards
Recent Milestones
Entered into acquisition agreement with Altaris LLC to be combined with Chemical Computing Group; Multiple FDA grants awarded; NIH SBIR Phase II $1.5M grant for RENAsym kidney injury model development; Expanded research agreement with NIEHS
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSimilar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.